Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROFILE real-world prospective observational study of sarilumab in adults with moderate to severe rheumatoid arthritis
MOH_2019-02-18_004799Phase 4Active, not recruiting
- Sponsor
- Sanofi
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sarilumab in rheumatoid arthritis (RA), sponsored by Sanofi. Primary endpoint: Change from baseline in Clinical Disease Activity Index. Started Feb 2019; status: active, not recruiting.
02
Drugs
sarilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on MOH_2019-02-18_004799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-18_004799.